To assess the safety and efficacy of three therapeutic regimens (foscarnet, ganciclovir, or
the combination) for recurrent or persistent AIDS-related cytomegalovirus (CMV) retinitis.
Although therapy with foscarnet or ganciclovir halts retinitis progression in 90 percent of
patients treated, relapses are common and may accelerate due to development of drug
resistance, deteriorating immune function, or other factors. Treatment strategies currently
being investigated include switching patients from one drug to the other or combining the two
drugs.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)